Autoimmune colitis and neutropenia in adjuvant anti-PD-1 therapy for malignant melanoma: efficacy of Vedolizumab, a case report

Autoimmune colitis and neutropenia in adjuvant anti-PD-1 therapy for malignant melanoma: efficacy of Vedolizumab, a case report

Immune checkpoint inhibitors (ICIs) represent an important advance in the adjuvant treatment of patients with high-risk melanoma. Although the safety profile of anti-programmed cell death protein-1 (PD-1) is fairly acceptable, different immune-related adverse events (irAEs) are described. Herein we...

Full description

Bibliographic Details
Main Authors: Maria d’Apolito, Rocco Spagnuolo, Maria Anna Siciliano, Vito Barbieri, Cristina Cosco, Lucia Fiorillo, Onofrio Cuomo, Valeria Zuccalà, Pierpaolo Correale, Licia Pensabene, Marco Rossi, Patrizia Doldo, Pierfrancesco Tassone, Pierosandro Tagliaferri
Format: Article
Language:English
Published: SAGE Publishing 2022-01-01
Series:Therapeutic Advances in Chronic Disease
Online Access:https://doi.org/10.1177/20406223211063024

Internet

https://doi.org/10.1177/20406223211063024

Similar Items